Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Assistant Director
Laboratory Medicine, Department of Pathology & Laboratory Medicine
Assistant Director
Clinical Laboratory, RPCI Amherst Center & Infusion Clinic
Roswell Park Cancer Institute
Profile
Areas of Expertise: 
Breast cancer (metastatic)
Colon cancer (metastatic)
Prostate cancer (metastatic)
Multiple myeloma
Research
Research Interests: 
Role of serum tumor markers in the diagnosis of metastatic breast, colon and prostate cancers
Using CTC assay to monitor efficacy of chemotherapy in biliary cancers
Combining imaging with CTC assay to monitor efficacy of chemotherapy in nonsmall cell lung cancer
Background Information
Education and Training: 
MD - University of Medicine and Pharmacy, Faculty of General Medicine, Bucharest, Romania
MSc - McGill University, Montreal, QC, Canada
Residency: 
Winthrop University Hospital, Mineola, NY
Board Certification: 
Anatomic Pathology, American Board of Pathology
Clinical Pathology, American Board of Pathology
Fellowships: 
Winthrop University Hospital, Mineola, NY
University of Texas, MD Anderson Cancer Center, Houston, TX
Publications
Publications: 
  • Chanan-Khan A, Lee K, Iancu D, Patel M, Barcos M, Bernstein ZP, Mohr A, Sher T, Ailawadhi S, Yu J, Padmanabhan S, Musial L, Miller KC, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia and lymphoma 2009; 50(7):1096-1101
  • Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology 2011; 154(1):104-110
  • Iancu DM. Correlation of serum free light chains (Freelite) with urine immunofixation (IFE) free light chains (FLC) in the diagnostic and follow-up of patients with intact immunoglobulin multiple myeloma (IIMM) in a comprehensive cancer center. Clinical chemistry 2009; 55(6 Suppl.):A115
  • Iancu DM, Handy BC, Fritsche HA. Interference with an immunoassay for CA 27.29 by a serum IgG kappa monoclonal protein. Clinical chemistry 2007; 53(6 Suppl.):C35
  • Al Ustwani O, Iancu D, Yacoub R, Iyer R. Detection of circulating tumor cells in cancers of biliary origin. Journal of gastrointestinal oncology 2012; 3(2):97-104
Source URL (retrieved on 06/19/2013 - 10:02am): http://www.roswellpark.org/dan-iancu